Novavax Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Welcome, everyone, to Jefferies 2026 Global Healthcare Conference in London. My name is Roger Song, senior analyst, covers biotech in the U.S. It is my great pleasure to have the fireside chat with Novavax. We have the full crew here. John Jacobs, CEO. Thank you, Roger.
Jim Kelly, CFO. Thanks, Roger.
Elaine O'Hara, the Chief Strategy Officer. We have Bob Walker, Head of R&D. Welcome, gentlemen, and then lady. Maybe, John, why not you start with, particularly for the investor who are relatively new to Novavax Yeah which they should not be.
Since you joined Novavax two years ago, launched a new strategy as a new CEO, what you have been achieved, what's the future look like, and why you're excited?
Roger, it's been a remarkable transformation of the company that we're very excited about. We've changed the company from a vaccine company focused on marketing its one asset at the time, which was a vaccine for COVID, and taking this technology platform, which is the reason I came here, phenomenal platform, and looking to share that more with the world through out-licensure and partnering. So we converted the company from a fully integrated global company selling one product in a pandemic to a company that out-licensed our tech with the goal of building value and revenue through partnering. I'm not sure if we lost audio here, guys, but we'll Should be all right.
I think you have it.
Okay. Look, we believe our technology can underpin a wide variety of vaccines in viral and bacterial targets and infectious disease, where we started and where we have proof of concept, and potentially in oncology, where we're in the stages of early exploration on how our technology might fit into that emerging ecosystem with vaccines.
When we look back just on 2026, we're very proud of our accomplishments as a team. Year two of this new strategy that we launched, we've had some significant milestones and achievements, including bringing Pfizer in as a new partner with a half billion dollar headline and potential milestones across two fields and a $30 million upfront for Pfizer to engage with and explore our technology, and hopefully bring forward more than one asset to help people in the future as a great partner.
We just earned, in the last month or so, a $125 million milestone from our ongoing partnership with Sanofi for their clinical initiation of a combination COVID-flu vaccine with their world-leading flu vaccine and our differentiated COVID vaccine, non-mRNA protein-based. That trial started in Europe. We earned that milestone. They also indicated their intention to start a combination vaccine trial in the U.S. market. As a reminder for our audience, should they achieve a first sale of a combination vaccine with our COVID vaccine in the U.S., we would be eligible to earn a $225 million milestone and ongoing royalties for potentially decades after the launch of these products.
We also, through the course of 2026, signed up additional initial partners through MTAs, or material transfer agreements, where these companies get to explore our technology in their own laboratories with the hopes that those too may turn into eventually license agreements for the company, similar to those of Pfizer and/or Sanofi. In addition, Roger, despite reducing our expenses between 80% and 90% over the last few years, we've maintained our capabilities to drive R&D. We make select investments in our R&D, and we use that to help fuel this partnering model.
Through the year, we have advanced our experiments with existing commercialized vaccines by adding our Matrix-M to many of those methodically, generating data that Elaine and her team can then go into potential partners with, existing partners with, and we can show them what their assets or their portfolio targets look like when they add our technology to hopefully foster more partnerships. Last but not least, we are advancing our own C. difficile vaccine with intention of being in the clinic as early as 2027, and again, with the primary intention about licensing that and generating more partnerships. That is 2026. We can talk later about what is ahead on catalysts, but very excited about where we are two years into this strategy right now.
Excellent. Thank you. Okay. This is a great overview.
Then let us talk each section in order. Novavax is no longer a one-product company, and then you have platform, you have a lot of partnership. COVID flu will still be the near-term value driver. Let us maybe just zoom in a little bit on that end. Take a step back. I think we have been through COVID, but it still persists.
Yes. How we think about the global COVID market, and then particularly in the context of the potential combination with the flu and the COVID?
Maybe who- Important question, Roger.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
